Jeff,

I share your disappointment, but while it is painful that we are still reaching for sufficient enrollment, better to have clean data, unlike remdesivir with apparently not-blinded results and neurocrine applying for rlf EUA on open label results.

EINDs are a great indication of efficacy, not proof that the world needs. We cannot have the world pivoting to a cure until it is proven, whether that is leronlimab or another therapeutic.